Immunogenomics for Drug Discovery in Leukemia
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 25 September 2025 | Viewed by 1547
Special Issue Editors
Interests: acute lymphoblastic leukemia; genomics; transcriptomics; hematological malignancies; breast cancer; mitochondria
Interests: acute lymphoblastic leukemia; myeloid leukemia
Special Issue Information
Dear Colleagues,
Leukemia is a group of hematological diseases that are highly heterogeneous in terms of their clinical, molecular and therapeutic response and remains an important cause of morbidity and mortality in children and adults. In fact, although leukemia treatment protocols have been improved during the last decade, the morbidity and mortality rates resulting from these diseases persist as an important public health problem in many populations. Since the Human Genome Project was launched, there have been notable advances in our understanding of the genomic basis of leukemia and the role of genetic mutations in relapse and chemoresistance. Therefore, more efforts are needed to discover new biomolecules for early diagnosis, the monitoring of residual disease, early detection of relapses, and the development of more suitable treatments for leukemia subtypes. This Special Issue aims to highlight current knowledge on the use of immunogenomics approaches to achieve personalized medicine to treat these diseases.
We encourage the submission of review papers and original manuscripts containing new and unpublished data related to omics studies and experimental models of leukemia with the aim of discovering new therapeutic approaches.
Dr. Silvia Jiménez-Morales
Dr. Adolfo Martínez-Tovar
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- leukemia
- hematological diseases
- immunogenomics
- omics studies
- experimental models
- therapeutic approaches
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
